Joel W Neal

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. pmc First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
    Kim Son H Nguyen
    Stanford Cancer Institute, Stanford University, Stanford, CA, USA
    Biologics 6:337-44. 2012
  2. doi request reprint Current management of small cell lung cancer
    Joel W Neal
    Stanford Cancer Institute, Department of Medicine, Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305 5826, USA
    Clin Chest Med 32:853-63. 2011
  3. doi request reprint Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh
    Joel W Neal
    Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Curr Treat Options Oncol 11:36-44. 2010
  4. pmc The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer
    Joel W Neal
    Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Future Oncol 6:1827-32. 2010
  5. doi request reprint Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era
    Jonathan W Riess
    Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA Department of Internal Medicine, University of California Davis School of Medicine Division of Hematology Oncology, University of California Davis Cancer Center, Sacramento, CA Electronic address
    Clin Lung Cancer 15:202-6. 2014
  6. pmc Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction
    Millie Das
    Department of Medicine, Division of Medical Oncology, Stanford University, Stanford, CA VA Palo Alto Health Care System, Palo Alto, CA
    Lung Cancer 89:280-6. 2015
  7. ncbi request reprint A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinib
    Jonathan W Riess
    Department of Medicine, Division of Oncology, Division of Neuro Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California 94305, USA
    J Natl Compr Canc Netw 11:389-94. 2013
  8. pmc Diffuse high intensity PD-L1 staining in thymic epithelial tumors
    Sukhmani K Padda
    Division of Oncology, Department of Internal Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA Division of Hematology Oncology, Department of Internal Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA Department of Pathology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA and Department of Health and Research Policy, Stanford University School of Medicine, Stanford, CA
    J Thorac Oncol 10:500-8. 2015
  9. ncbi request reprint GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray
    Jonathan W Riess
    Department of Medicine, Division of Hematology Oncology, University of California Davis Comprehensive Cancer Center, University of California Davis School of Medicine, Sacramento, CA, U S A Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, U S A
    Anticancer Res 35:669-76. 2015
  10. pmc An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
    Aaron M Newman
    1 Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California, USA 2 Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, California, USA 3
    Nat Med 20:548-54. 2014

Collaborators

Detail Information

Publications14

  1. pmc First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
    Kim Son H Nguyen
    Stanford Cancer Institute, Stanford University, Stanford, CA, USA
    Biologics 6:337-44. 2012
    ..Here we review the major trials leading to the established use of EGFR TKIs in NSCLC, followed by discussion of recently completed and ongoing trials using the next-generation EGFR inhibitor afatinib...
  2. doi request reprint Current management of small cell lung cancer
    Joel W Neal
    Stanford Cancer Institute, Department of Medicine, Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305 5826, USA
    Clin Chest Med 32:853-63. 2011
    ..Numerous promising targeted therapies and other agents are still in development...
  3. doi request reprint Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh
    Joel W Neal
    Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Curr Treat Options Oncol 11:36-44. 2010
    ..Inhibitors of the hedgehog (Hh) signaling pathways have some early clinical promise in both NSCLC and small cell lung cancer (SCLC), and larger studies using these agents are eagerly anticipated...
  4. pmc The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer
    Joel W Neal
    Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Future Oncol 6:1827-32. 2010
    ..A subset of patients whose tumors had EGF receptor mutations had a higher magnitude of benefit from maintenance treatment. Therefore, maintenance erlotinib should be considered in the treatment of patients with NSCLC...
  5. doi request reprint Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era
    Jonathan W Riess
    Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA Department of Internal Medicine, University of California Davis School of Medicine Division of Hematology Oncology, University of California Davis Cancer Center, Sacramento, CA Electronic address
    Clin Lung Cancer 15:202-6. 2014
    ..Leptomeningeal carcinomatosis (LM) is a severe complication of non-small-cell lung cancer (NSCLC) historically associated with poor prognosis. New chemotherapeutic and targeted treatments could potentially affect the natural history of LM...
  6. pmc Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction
    Millie Das
    Department of Medicine, Division of Medical Oncology, Stanford University, Stanford, CA VA Palo Alto Health Care System, Palo Alto, CA
    Lung Cancer 89:280-6. 2015
    ..This phase 1 trial was conducted to characterize the safety and determine the maximum tolerated dose of erlotinib plus dovitinib in patients with previously treated metastatic non-small cell lung cancer...
  7. ncbi request reprint A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinib
    Jonathan W Riess
    Department of Medicine, Division of Oncology, Division of Neuro Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California 94305, USA
    J Natl Compr Canc Netw 11:389-94. 2013
    ....
  8. pmc Diffuse high intensity PD-L1 staining in thymic epithelial tumors
    Sukhmani K Padda
    Division of Oncology, Department of Internal Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA Division of Hematology Oncology, Department of Internal Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA Department of Pathology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA and Department of Health and Research Policy, Stanford University School of Medicine, Stanford, CA
    J Thorac Oncol 10:500-8. 2015
    ..PD-L1 protein expression by immunohistochemistry is emerging as a predictive biomarker of response to these therapies. Here, we examine PD-L1 expression in a thymic epithelial tumor (TET) tissue microarray (TMA)...
  9. ncbi request reprint GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray
    Jonathan W Riess
    Department of Medicine, Division of Hematology Oncology, University of California Davis Comprehensive Cancer Center, University of California Davis School of Medicine, Sacramento, CA, U S A Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, U S A
    Anticancer Res 35:669-76. 2015
    ....
  10. pmc An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
    Aaron M Newman
    1 Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California, USA 2 Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, California, USA 3
    Nat Med 20:548-54. 2014
    ..Finally, we evaluated biopsy-free tumor screening and genotyping with CAPP-Seq. We envision that CAPP-Seq could be routinely applied clinically to detect and monitor diverse malignancies, thus facilitating personalized cancer therapy. ..
  11. doi request reprint Aflibercept in lung cancer
    Joel W Neal
    Stanford University Stanford Cancer Institute, Department of Medicine Oncology, Stanford, CA, USA
    Expert Opin Biol Ther 13:115-20. 2013
    ..Aflibercept (VEGF Trap) is a recombinant VEGF receptor-antibody protein fusion with higher affinity for VEGF-A than bevacizumab, plus affinity for VEGF-B and placental growth factor (PlGF)...
  12. doi request reprint Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects
    Jody C Chuang
    Division of Hematology and Oncology, Stanford Hospital and Clinics, Stanford, CA, USA
    Lung Cancer 90:1-7. 2015
    ..Questions remain, however, about whether these agents can improve cure rates for early stage lung cancers in the adjuvant setting. Here, we examine the current data and ongoing trials addressing this issue. ..
  13. pmc Review of the current targeted therapies for non-small-cell lung cancer
    Kim Son H Nguyen
    Kim Son H Nguyen, Joel W Neal, Heather Wakelee, Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States
    World J Clin Oncol 5:576-87. 2014
    ..The identification of specific molecular targets in a significant fraction of NSCLC has led to the personalized deployment of many effective targeted therapies, with more to come. ..
  14. doi request reprint Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients
    Jonathan W Riess
    Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA
    Immunopharmacol Immunotoxicol 36:182-6. 2014
    ....